Cite
HARVARD Citation
Wanner, C. et al. (2020). Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA‐REG OUTCOME trial. Diabetes, obesity & metabolism. 22 (12), pp. 2335-2347. [Online].